scispace - formally typeset
B

Bichitra K. Biswal

Researcher at University of Alberta

Publications -  45
Citations -  795

Bichitra K. Biswal is an academic researcher from University of Alberta. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 13, co-authored 37 publications receiving 705 citations. Previous affiliations of Bichitra K. Biswal include Indian Institute of Science & Canadian Institutes of Health Research.

Papers
More filters
Journal ArticleDOI

Crystal structures of the RNA dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.

TL;DR: The structures of the NS5B polymerase/non-nucleoside inhibitor complexes bind at a common binding site, which is nearly 35 Å away from the polymerase active site and is located in the thumb domain, and the enzyme inhibitor complexes are stabilized by hydrogen bonding and van der Waals interactions.
Journal ArticleDOI

Mammalian zona pellucida glycoproteins: structure and function during fertilization.

TL;DR: In humans more than one zona protein binds to spermatozoa and induces an acrosome reaction, and Sialyl-Lewisx sequence present on both N- and O-glycans of human ZP play an important role in human sperm–egg binding.
Journal ArticleDOI

Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.

TL;DR: The details of NS5B polymerase/inhibitor binding interactions coupled with the observed induced conformational changes provide new insights into the design of novel NNIs of HCV.
Journal ArticleDOI

Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S

TL;DR: It is demonstrated that clinically potent gold derivatives inhibit cathepsins K and S in in vitro and cell-based assays and may explain the therapeutic efficacy of these drugs.
Journal ArticleDOI

The molecular structure of epoxide hydrolase B from Mycobacterium tuberculosis and its complex with a urea-based inhibitor.

TL;DR: These findings have not only shed light on the enzyme mechanism but also have opened a path for the development of potent inhibitors with good pharmacokinetic profiles against all Mtb EHs of the alpha/beta type.